![]() | |
Clinical data | |
---|---|
Routes of administration | Oral, intransal, vaporized |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C21H26N4O3 |
Molar mass | 382.464 g·mol−1 |
3D model (JSmol) | |
| |
|
N-Desethylprotonitazene is a benzimidazole opioid with potent analgesic effects which has been sold as a designer drug. It was first identified in 2024 as an active metabolite of the closely related compound protonitazene, [1] [2] and was found to have less potency than it while still being more potent than fentanyl. [3] [4]
It was discovered in a drug sample from Chicago in June 2025. [3]